Literature DB >> 2624597

Synthesis and absolute configuration of the new thromboxane antagonist (3R)-3-(4-fluorophenylsulfonamido)-1,2,3,4-tetrahydro-9-carbazolepropan oic acid and comparison with its enantiomer.

U Rosentreter1, H Böshagen, F Seuter, E Perzborn, V B Fiedler.   

Abstract

The synthesis of (3R)-3-(4-Fluorophenylsulfonamido)-1,2,3,4-tetrahydro-9- carbazolepropanoic acid (Bay u 3405), a new, enantiomerically pure antagonist of thromboxane A2, is described. The determination of the absolute configuration of Bay u 3405 was performed by an X-ray analysis of compound 7 ([3((2S)-acetylamido)-3-phenylpropionamido]-1,2,3,4- tetrahydro-carbazol). Bay u 3405 is in vitro 1 to 2 orders of magnitude more active than its (-)-enantiomer Bay u 3406.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2624597

Source DB:  PubMed          Journal:  Arzneimittelforschung        ISSN: 0004-4172


  2 in total

1.  Thromboxane A2 (TXA2) receptor blockade suppresses monocyte chemoattractant protein-1 (MCP-1) expression by stimulated vascular endothelial cells.

Authors:  T Ishizuka; S Sawada; K Sugama; A Kurita
Journal:  Clin Exp Immunol       Date:  2000-04       Impact factor: 4.330

2.  BAY u3405, a potent and selective thromboxane A2 receptor antagonist on airway smooth muscle in vitro.

Authors:  M G McKenniff; P Norman; N J Cuthbert; P J Gardiner
Journal:  Br J Pharmacol       Date:  1991-11       Impact factor: 8.739

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.